At final assessment , mirabegron was significantly superior to placebo in terms of mean -LSB- sd -RSB- change from baseline in number of micturitions/@h ( -@ -LSB- @ -RSB- vs -@ -LSB- @ -RSB- ; P < @ ) and mean -LSB- sd -RSB- change from baseline in number of urgency episodes/@h ( -@ -LSB- @ -RSB- vs -@ -LSB- @ -RSB- ; P = @ ) , incontinence episodes/@h ( -@ -LSB- @ -RSB- vs -@ -LSB- @ -RSB- ; P = @ ) , urgency incontinence episodes/@h ( -@ -LSB- @ -RSB- vs -@ -LSB- @ -RSB- ; P = @ ) , and volume voided/micturition ( @ -LSB- @ -RSB- vs @ -LSB- @ -RSB- mL ; P < @ ) .